PLRX (STOCKS)
Pliant Therapeutics, Inc. Common Stock
$1.140000
+0.010000 (+0.88%)
Prev close: $1.130000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Bernard Coulie
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $70.28M
- Employees
- 171
- P/E (TTM)
- -0.62
- P/B (TTM)
- 0.42
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $119.21M |
| Research and Development | $79.31M |
| Other Operating Expenses | $39.91M |
| Operating Income/Loss | -$119.21M |
| Income/Loss From Continuing Operations After Tax | -$113.22M |
| Income/Loss From Continuing Operations Before Tax | -$113.22M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$113.22M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$113.22M |
| Net Income/Loss Available To Common Stockholders, Basic | -$113.22M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.84 |
| Diluted Earnings Per Share | -$1.84 |
| Basic Average Shares | 184,623,894 |
| Diluted Average Shares | 184,623,894 |
| Common Stock Dividends | $0.00 |
| Assets | $202.60M |
| Current Assets | $174.93M |
| Noncurrent Assets | $27.67M |
| Fixed Assets | $2.66M |
| Other Non-current Assets | $25.00M |
| Liabilities | $37.43M |
| Current Liabilities | $10.36M |
| Accounts Payable | $362.00K |
| Wages | $2.29M |
| Other Current Liabilities | $7.71M |
| Noncurrent Liabilities | $27.07M |
| Long-term Debt | $0.00 |
| Equity | $165.17M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $165.17M |
| Liabilities And Equity | $202.60M |
| Net Cash Flow From Operating Activities | -$98.70M |
| Net Cash Flow From Operating Activities, Continuing | -$98.70M |
| Net Cash Flow From Investing Activities | $61.08M |
| Net Cash Flow From Investing Activities, Continuing | $61.08M |
| Net Cash Flow From Financing Activities | -$32.12M |
| Net Cash Flow From Financing Activities, Continuing | -$32.12M |
| Net Cash Flow | -$69.75M |
| Net Cash Flow, Continuing | -$69.75M |
| Comprehensive Income/Loss | -$113.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$113.72M |
| Other Comprehensive Income/Loss | -$70.26M |
| Other Comprehensive Income/Loss Attributable To Parent | -$500.00K |